26 октября 2017

Sechenov University held an International Conference on Personalized Oncology on October 12, 2017. Under the framework of the project “Sechenov Live” we’ve talked about the significance of Personalized Oncology with some foreign experts of the conference.

dzhon-mendelson.jpgJohn Mendelsohn (Institute of Personalized Cancer Therapy & Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, USA): "I think that personalized Oncology is a new dimension of the medical science alongside with surgery, concurrent chemotherapy and radiation therapy. It promises new frontiers of survival of patients, new methods of diagnosis and therapy. I'm impressed by the level of concerment and understanding of the problems here in Russia and  particularly at Sechenov University. Russian medicine, biology and natural sciences have a long and glorious history from the Mendeleev Periodic Table to modern physics, mathematics, statistics, analytics. The Russian scientists have achievements in prevention of several diseases, in treatment of tuberculosis or pneumonia, which today are became the top leading causes of human deaths in the world.Today you stand a bit behind in Oncology,nevertheless using the right tools will help to overcome the problems. Some of the tools we’ve presented at the conference. Personalized Oncology means very different things to different people.For example, the last five years the main emphasis was made on genes associated with predisposition to various diseases. Today the focus has shifted to study of ribonucleic acid and proteins, as well as determination of tumor microenvironment and immune response to tumor attack. We are studying the impact of prevention measures on cancer diseases, and possibility to reduce its value by eliminating the social causes, such as the habit of overeating, and especially smoking. It would be much more effective if you stop smoking and lose some weight, but not just take a genetic test."

devid-smit.jpgDavid Smith (Department of laboratory medicine and pathology, Technology Assessment Committee, Center for Personalized Medicine, Mayo Clinic, Rochester, USA):

"I am pleasantly surprised that the discussion of Predictive Oncology is developing in Russia. Predictive Oncology still depends on the development of genetics. So I talk about prospects of genome-wide sequence analysis for the treatment of oropharyngeal cancer treatment.Cancer disease is directly related to smoking, it is still very important today. Applying knowledge about the genetic polymorphisms associated with a particular tumor (or with the body's response to a particular tumor) helps us to choose a strategy of management of a particular patient in the future".

vladimir-lazar.jpgVladimir Lazar (WIN Consortium, Paris, France):

" I represent a large consortium of cancer researchers. Its membership includes representatives from 19 countries. This year Sechenov University officially became a part of our organization. Our mission is to organize different kinds of activities in the world of Oncology, as well as promotion of new technologies for the treatment of cancer diseases. I am happy such a representative event has been organized in Moscow.  I’ll make a report on the prospects for use of biomarkers to predict the effect of targeted therapy of lung cancer. Lung cancer is in the main focus of our consortium in 2017. It is the most virulent kind of cancer diseases. Our consortium maintains contacts with Russian colleagues. Under the framework of the OncoTarget project by Sechenov University we collaborates with the organizer of the conference Professor Marina Sekacheva ".

rozhder-kamm.jpgRoger Kamm (NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems, MIT, Cambridge,  Massachusetts, USA):

"Microfluidics plays an important role in medicine of the future and the personalized Oncology.  Due to inexpensive chips it is possible to do research on different aspects of cancer. For example, is crucial to understand how tumor cells metastasize and how they overcome different kinds of vascular barriers. Microfluidic technology will allow more accurate use medicines.They can be pre-tested on a live system with the cells of the patient, but not on the patient himself. Without this technology personalized medicine wouldn’t work.Moreover, due to the abundance of low cost chips, we could dramatically reduce the cost of drug discovery.For example, it’s important that now drug discovery that can cross the blood-brain barrier and our developments will help future scientists. It’ s a wonderful  possibility to introduce it such an important conference, which is held in Russia."

marina-sekacheva.jpgMarina Sekacheva, Center for Personalized Oncology “OncoTarget” (Sechenov University), organizer of the Conference:

"Personalized Oncology is important for three reasons. Firstly, cancer is a really life- threatening disease and not just affect on the quality of human life. Due to the diagnostic procedure on the early stages we can save these people. Early diagnostics will allow cancer disease to be simply recovered. Secondly, antitumor drugs have a large range of drug side effects. It’s important to take into consideration the individual characteristics of each patient, to bring maximum benefit and cause minimum harm. Thirdly, early diagnosis and optimization of treatment strategies will provide a significant burden reduction on the healthcare system.The conference has allowed us to discuss advanced strategies in this field with our foreign colleagues".

про COVID-19